Clinical Trials Logo

Endogenous Cushing's Syndrome clinical trials

View clinical trials related to Endogenous Cushing's Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT05382156 Recruiting - Clinical trials for Endogenous Cushing's Syndrome

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

LINC6
Start date: June 13, 2022
Phase:
Study type: Observational

This is a non-interventional, multinational, multi-centre study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in patients treated with osilodrostat for endogenous Cushing's Syndrome

NCT ID: NCT03880513 Completed - Clinical trials for Endogenous Cushing's Syndrome

Cardiovascular Status in Patients With Endogenous Cortisol Excess (Cushing's Syndrome)

CV-CORT-EX
Start date: October 2014
Phase:
Study type: Observational [Patient Registry]

Within this trial, the cardiovascular and mental status as well as the metabolic profiles of patients with endogenous cortisol excess are evaluated.

NCT ID: NCT03277690 Completed - Clinical trials for Endogenous Cushing's Syndrome

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.

Start date: September 26, 2017
Phase: Phase 3
Study type: Interventional

This is a double-blind, randomized, placebo-controlled withdrawal and rescue/restoration study in subjects with endogenous Cushing's Syndrome (CS) previously treated with single-arm, open-label levoketoconazole that will assess efficacy, safety, tolerability, and pharmacokinetics of levoketoconazole.

NCT ID: NCT01838551 Completed - Clinical trials for Endogenous Cushing's Syndrome

Treatment for Endogenous Cushing's Syndrome

SONICS
Start date: August 2014
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to evaluate the clinical responder rate, defined as the proportion of subjects with normal UFC after 6 months of treatment with COR-003 in the Maintenance Phase without dose increase, and to evaluate the range of effective doses in subjects with various levels of hypercortisolism.